Clinical Trial Update: Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of zanubrutinib, ixazomib, and dexamethasone in treatment-naive Waldenström macroglobulinemia has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Zanubrutinib (zanubrutinib)
• ixazomib (ixazomib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Waldenström Macroglobulinemia | Phase 2 | Status: COMPLETED